A comparative Study of Immunohistochemical Expression of Tumor Necrosis Factor-Alpha, Interleukin-6and Vascular Endothelial Growth Factor in Giant Cell Granuloma of the Jaws and Giant Cell Tumor of Long Bones

Saba F. Naji, Wasan H. Younis, Bashar H. Abdullah


Background: Central giant cell granuloma (CGCG) and peripheral giant cell granuloma(PGCG) are pathological conditions of the jaws that share the same microscopic features, but differ clinically in terms of their behavior. While the giant cell tumor (GCT) of long bones is a rare benign neoplasm, tend to affect femur and tubular bone, characterized by local aggressiveness, high recur- rence rates and metastasis to the lung.

Objectives: To evaluate, compare and correlate the expression of TNF-α, IL-6 and VEGF in peripheral and central giant cell granu- loma of the jaw and giant cell tumor of long bones.
Methods: A total of 60 retrospective formalin- fixed, paraffine-embeded specimens of giant cell lesions of the jaws and long bones, where included in this study. An immunohistochemical staining with TNF-α , IL-6 and VEGF monoclonal antibodies were performed.

Results: TNF-α, IL-6 and VEGF were expressedin all lesions. The PGCG comparedto the CGCG and GCT showed significantly in- creased expression of TNF-α and decreased expression of VEGF by the stromal cells..GCT showed increased expression of VEGF by M NGCs and stromal cells .There is a non significant difference between CGCG and GCT regarding the expression of all three cytokines.

Conclusions: The present study confirmed the usefulness TNF-α,IL-6 and VEGF in evaluating osteoclastogenesis. The results of this study proved that the biological activity of TNF-α, IL-6 and VEGF was comparable between the central giant cell granuloma and giant cell tumors, supporting the observations that these two lesions are the same entity and have the same biological behavior. 


central giant cell granuloma; Peripheral giant cell granuloma;Giant cell tumor

Full Text:



Neville, B.W ; Damm, D.D : Bouqout, J.E. Oral maxillo facial pathology. WB. Saunders Company. 2005:p550 .

Corso E De , M Politi, [...], and G Paludetti Advanced giant cell reparative granuloma of the mandible: radiological features and surgical treatment.Acta Otorhinolaryngol 2006(3):168-172.

Neville, B.W; Damm,D.D; Allen,C.M;Bouquot,J.E. Bone Pathology. n: Oral and Maxillofaci l Pathology 3rd ed..WB. Sanders, Philadeiphia. 2009 ;14: 507-629

Chaparro-Avendaño AV, Berini-AytésL, Gay-Escoda C. Peripheral giant cell granuloma. Areport offive cases and review ofthe literature. Med Oral Patol Oral Cir Bucal.2005;10:53-7; 48-52

McGough RL, Rutledge J, Lewis VO,Lin PP andYasko AW. Impact severity of local recurrence in giant cell tumor of bone.Ciin Orthop Re at Res 2005;438:116-122

Werner M. Giant cell tumor of bone : morphological, biological and histogenetical aspects. In t orthop 2006;30-489

Lanza A., Luigi Laino, [...], and Nicola Cirillo Clinical Practice: Giant Cell Tumour of the Jaw Mimicking Bone Malignancy on Three-Dimensional Computed Tomography (3D CT) Reconstruction. Open Dent .J. 2008,2:174-178.

Bilodeau E, Khalid Chowdhury and Bobby Collins A Case of Recurrent Multifocal Central Giant Cell Granulomas.Head&neck pathol.2009;3(2):174-178

Sophie R, Larbi A, Geri M, Anne, G-M, Edwin, Xavie M..RANK(receptor activator nuclear factor kappa B)and RANK ligand are expressedin giant cell tumor of bone.Am J Clin Pathol.2002;117(2): 210-17

Tobón SI, Franco-González LM, Isaza-Guzmán DM, Floréz-Moreno GA, Bravo-Vásquez T, Castañeda-Peláez DA, et al. Immunohistochemical expression of RANK, GR alpha and CTR in central giant cell granuloma of the jaws. Oral Oncol.2005;41:480-8.

Papanicolaou P, Chrysomali E, Stylogianni E, Donta C, Vlachodimitripoulos D Increased TNF-α, IL-6 and decreased IL-1β immunohistochemical expression by the stromal spindle-shaped cells in the central giant cell granuloma of the jaws Med Oral Patol Oral Cir Bucal. 2012;17 (1): 56-62

Flo´ rez-Moreno GA, Henao-Ruiz M, Santa-Sa´ enz DM, Castan˜ eda-Pela´ ez DA, Tobo´ n-Arroyave SI. Cytomorphometric and immunohistochemical comparison between central and peripheral giant cell lesions of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105: 625–32.

Amaral FR, Brito JA, Perdigao PF, et al. NFATc1 and TNF alpha expression in giant cell lesions of the jaws. J Oral Pathol Med 2010; 39: 269–74.

De Matos FR,De Moraes M, Nonak CF, De Souza LB, Freitas RA.. Immunoexpression of TNF-a and TGF-b in central and peripheral giant cell lesions of the jaws J Oral Pathol Med 2012; 41:194–199

Matos FR, Nonaka CF, Miguel MC, Galvao HC, Souza LB, Freitas RA. Immunoexpression of MMP-9, VEGF, and vWF in central and peripheral giant cell lesions of the jaws. J Oral Pathol Med 2011; 40: 338–44.

Abdul Khafoor S. Histopathological and Immunohistochemical expression nf (RANK), (TNF) & (ALP) markers in giant cell tumor of bone and central giant cell granuloma of the jaw. A master thesis, Oral Medecine, Department of Oral Diagnosis, University of Baghdad 2008.

Gamberi G, Benassi MS, Ragazzini P, Pazzaglia L, Ponticelli F, Ferrari C, et al.Proteasesandinterleukin-6 gene analysisin 92 giant cell tumorsofbone.Ann Oncol 2004;15:498-503.

Dai JC, He P, Chen X, Greenfield EM. TNF alpha and PTH utilize distinct mechanismsto in-duce IL-6 and RANKL expression ithmarkedly different kinetics.Bone 2006;38:509-20.

Vered M, Buchner A, Dayan D. Giant cell granuloma of the jaw bones: a proliferative vascular lesion? Immunohistochemical study with vascular endothelial growth factor and basic fibroblastic growth factor. J Oral Pathol Med. 2006;35(10):613-9.

Souza PE, Mesquita RA, Gomez RS. Evaluation of p53, PCNA, Ki-67, MDM2 and AgNOR in oral peripheral and central giant cell lesions. Oral Dis. 2000; 6: 35–9

Araga˜o M do S, Piva MR, Nonaka CF, Freitas Rde A, de Souza LB, Pinto LP. Central giant cell granuloma of the jaws and giant cell tumor of long bones: an immunohistochemical comparative study. J Appl Oral Sci 2007; 15: 310–6.

Kumta SM, Huang L, Cheng YY, Chow LT, Lee KM, Zheng MH. Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci 2003; 73: 1427–1436.

Lehmann W.,, C.M. Edgar, K. Wang, T-J. Cho, G.L. Barnesa, S. Kakar, D.T. Gravesd, J.M. Rueger, L.C. Gerstenfelda, T.A. Einhorna, Tumor necrosis factor alpha (TNF-α) coordinately regulates the expression of specific matrix metalloproteinases (MMPS) and angiogenic factors during fracture healing Bone 2005; 36, (2): 300–310

Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005; 9: 267–85

Engsig MT, Chen QJ, Vu TH, Pedersen AC, Therkidsen B, Lund LR, Henriksen K, Lenhard T, Foged NT, Werb Z & Delaissé JM. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol 2000; 151: 879–889

Parameswaran N, Patial S. Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr 2010; 20: 87–103

Kobayashi, K, Takahashi, N, JIMI, E, UDAGAWA, N, TAKAMI, M, KOTAKE, S, NAKAGAWA, N et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. The Journal of Experimental Medicine 2000; 191; p. 275-286.

Lam, J., S. Takeshita, J.E. Barker, O. Kanagawa, F.P. Ross, and S.L. Teitelbaum. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 2000; 106:1481–1488

Kurokouchi, K, Kambe, F, Yasukawa K, Izumi R, IshiguroN, Iwata, H and Seo, H. TNF-alpha increases expression of IL-6 and ICAM-1 genes through activation of NFkappab in osteoblast-like ROS17/2.8 cells. Journal of Bone and Mineral Research 1998; 13: 1290-1299.

DOI: http://dx.doi.org/10.26477/idj.v38i2.81


  • There are currently no refbacks.